Clinical trial
ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell…
NCT00140660 · Lymphoma Study Association, Other · Terminated
Key facts
| NCT number | NCT00140660 |
|---|---|
| Title | ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma |
| Official title | Randomized Study of ACVBP Versus ACVBP Plus Rituximab in Previously Untreated Patients Aged From 18 to 65 Years With Low-risk Localized Diffuse Large B-cell Lymphoma (Age-adjusted IPI = 0) |
| Lead sponsor | Lymphoma Study Association, Other |
| Collaborators | Amgen Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diffuse Large Cell Lymphoma |
| Intervention type | Drug |
| Interventions | rituximab |
| Enrollment | 223 |
| Start date | Dec 1, 2003 |
| Primary completion | Jul 1, 2008 |
| Completion | Apr 1, 2012 |
| First posted | Sep 1, 2005 |
| Last update posted | Mar 13, 2017 |
| Countries | Belgium, France, Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: